DermTech
6
0
0
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
A Prospective Multicenter Sample Collection Study Using Non-invasive Methods to Investigate Mutation Burden in Non-lesional Facial Skin of Patients With a Hx of Skin Cancer
Role: lead
Sample Collection Study in Patients With Suspected Melanoma Utilizing DermTech's Non-invasive Adhesive Patch Biopsy Kits
Role: lead
A Prospective Sample Collection Study Using Non-invasive Methods to Investigate Biomarkers in AD Patients
Role: lead
A Sample Collection Study Utilizing DermTech's Non-invasive Adhesive Patch Biopsy Kits
Role: lead
Sample Collection Study to Assess Prevalence of Gene Mutations: Establishing Population Norms
Role: lead
DermTech's Non-Invasive Pigmented Lesion Assay to Detect and Track Lesions for Suspected Melanoma and to Determine Outcomes for up to 2 Years
Role: lead
All 6 trials loaded